NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Anbio Biotechnology
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$3.27+0.14 (+4.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 22.2
- Dividend yield
- –
SEC filings
10 of Anbio Biotechnology's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 6-K | May 19, 2026 | May 19, 2026 | SEC EDGAR |
| Current report | 6-K | Apr 27, 2026 | Apr 27, 2026 | SEC EDGAR |
| Annual report, amended | 20-F/A | Dec 31, 2025 | Apr 9, 2026 | SEC EDGAR |
| Annual report | 20-F | Dec 31, 2025 | Apr 7, 2026 | SEC EDGAR |
| Current report | 6-K | Feb 17, 2026 | Feb 17, 2026 | SEC EDGAR |
| Current report | 6-K | Jan 26, 2026 | Jan 26, 2026 | SEC EDGAR |
| Current report | 6-K | Dec 30, 2025 | Dec 30, 2025 | SEC EDGAR |
| Current report | 6-K | Nov 12, 2025 | Nov 13, 2025 | SEC EDGAR |
| Annual report | 20-F | Dec 31, 2024 | Apr 28, 2025 | SEC EDGAR |
| Current report | 6-K | Feb 21, 2025 | Feb 21, 2025 | SEC EDGAR |